GlaxoSmithKlineThe Impact of Medicines: Sustainability in Environment, Health and Safety Report 2002
Reporting Front PageDownloads
EHS 2002 home

About this report

Executive statements

Framework

Issues

Performance

Verification statement

Index
Index
Previous
Next
 
 
J
K
Q
U
X
Y
Z
Accident
Air emissions
Air pollution
Animal testing
Audit
Awards
Biodiversity
Capital
Chairman of the Board
Chemical Oxygen Demand (COD)
Chief Executive Officer
Climate change
Contaminated land
Costs
Driver safety
Emissions
Employee health
Environment
Ergonomics
Exposure limits
Fines
Framework
Genetically modified organisms (GMO)
Global Reporting Initiative (GRI)

Vision and Strategy (GRI: 1.1 and 1.2)

Profile (GRI: 2.1 to 2.22)

Governance Structure and Management Systems (GRI: 3.1 to 3.20)

Performance Indicators (GRI Section 5)
Global warming
Green chemistry
GSK
Guidelines
Hazard
Hazard communication
Hazardous waste
Health and safety
Human immunodeficiency virus (HIV)
Illness
Injury
International Standards Organisation (ISO)
Landfill
Lost time
Management systems
Material safety data sheet (MSDS)
Mental illness
Natural resources
Notice of violation
Occupational hygiene
Operations and maintenance
Organisation
Ozone depletion
Penalties
Performance
Pharmaceuticals in the environment
Photochemical ozone creation potential (POCP)
Planning
Process safety
Product stewardship
Recycle
Report scope
Reward and recognition
Safety engineering
Social responsibility
Solvent selection
Solvents
Stakeholders
Strategy
Superfund
Suppliers
Sustainability
Sustainable development
Targets
Vision
Volatile organic compounds (VOC)
Waste
Waste disposal
Wastewater
Water
Water pollution

 

 



Previous
Next


Top


EHS 2002 Home | Reporting Front Page | Downloads | Main Site
 
Updated July 21, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement